GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyowa Kirin Co Ltd (TSE:4151) » Definitions » Research & Development

Kyowa Kirin Co (TSE:4151) Research & Development : 円69,927 Mil (TTM As of Sep. 2023)


View and export this data going back to 1949. Start your Free Trial

What is Kyowa Kirin Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Kyowa Kirin Co's Research & Development for the three months ended in Sep. 2023 was 円17,520 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 was 円69,927 Mil.


Kyowa Kirin Co Research & Development Historical Data

The historical data trend for Kyowa Kirin Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyowa Kirin Co Research & Development Chart

Kyowa Kirin Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45,659.00 53,511.00 52,312.00 57,679.00 62,896.00

Kyowa Kirin Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16,232.00 18,753.00 16,619.00 17,035.00 17,520.00

Kyowa Kirin Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円69,927 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyowa Kirin Co  (TSE:4151) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Kyowa Kirin Co Research & Development Related Terms

Thank you for viewing the detailed overview of Kyowa Kirin Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyowa Kirin Co (TSE:4151) Business Description

Traded in Other Exchanges
Address
1-9-2,Otemachi, Chiyoda-ku, Otemachi Financial City Grand Cube, Tokyo, JPN, 100-0004
Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.

Kyowa Kirin Co (TSE:4151) Headlines

No Headlines